J. Kosek

发表

Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation

B. Tycko, N. Schupf, E. Hod, 2008, Nature Genetics.

Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity

E. Hur, J. Kosek, P. Schafer, 2017, The Journal of Immunology.

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

J. Kosek, S. Surapaneni, P. Schafer, 2012, Cancer Chemotherapy and Pharmacology.

Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study

E. Hur, J. Kosek, A. Kivitz, 2019, Rheumatology and Therapy.

Correlation of tumoricidal activity of lenalidomide against hematologic tumor cells with cyclin D1/D2 expression and effect on tumor-suppressor gene upregulation.

J. Kosek, P. Schafer, Ling-hua Zhang, 2010 .

CC-122 Is a Novel Pleiotropic Pathway Modifier with Potent in Vitro Immunomodulatory and Anti-Angiogenic Properties and in Vivo Anti-Tumor Activity in Hematological Cancers.

R. Chopra, Lei Wu, J. Kosek, 2012 .

Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expression

R. Chopra, J. Kosek, P. Schafer, 2012, British journal of haematology.

Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.

Lei Wu, Lei Wu, J. Kosek, 2016, Cellular signalling.

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.

M. Trotter, C. Fontanillo, A. Klippel, 2015, Blood.

Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus

R. Chopra, Lei Wu, J. Kosek, 2018, Annals of the rheumatic diseases.

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.

M. Trotter, C. Fontanillo, A. Klippel, 2015, Blood.

Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.

Lei Wu, J. Kosek, A. Marconi, 2016, Cellular signalling.